Stock Analysts

Savara to Stop Study on Molgradex for NTM Lung Infection

Savara Inc. SVRA announced that it has decided to discontinue the phase IIa exploratory clinical study ENCORE, which is evaluating its lead pipeline candidate Molgradex (molgramostim nebulizer solution) for the treatment of nontuberculous mycobacterial (NTM) lung infection in people living with cystic fibrosis (CF). […]

Stock Analysts

Akebia Falls as Vadadustat Fails to Meet Safety Endpoint

Akebia Therapeutics, Inc. AKBA announced top-line results from the second study of its two phase III cardiovascular outcomes programs — collectively called PRO2TECT — on vadadustat, an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor. The studies evaluated the efficacy and safety of vadadustat compared with Amgen’s AMGN Aranesp for the treatment of anemia due to chronic kidney disease (CKD) in adult patients who are not receiving dialysis. […]

Stock Analysts

Key Reasons for Airline Stocks’ Resilience Despite Challenges

It is no longer news that the Airline industry remains one of the worst-hit corners of the investing space amid the ongoing coronavirus pandemic. However, despite the existing challenges, shares of heavyweights like American Airlines AAL , Delta Air Lines DAL , United Airlines UAL , Southwest Airlines LUV and Alaska Air Group ALK have appreciated 14.7%, 21.2%, 14.9%, 23.3% and 16.5%, respectively, over the past month. […]

Stock Analysts

How to Invest After the Market Selloff

If you’re concerned about the way shares dropped off sharply yesterday, you should be. This kind of volatility is what we’ve been talking about for a while now, so it should be something we are preparing for rather than something that surprises us. It’s clear that there has been some profit taking, considering the long weekend coming up and the weather that generally has people visiting the great outdoors. […]